IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1026-1050 out of 1299.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

Public Release: 2-Jul-2015
European Heart Journal
Experts call for 'all hands on deck' to tackle global burden of non-communicable disease
A group of the world's top doctors and scientists working in cardiology and preventive medicine have issued a call to action to tackle the global problem of deaths from non-communicable diseases, such as heart problems, diabetes and cancer, through healthy lifestyle initiatives. Their suggestions to prevent or delay health conditions that cause the deaths of over 36 million people worldwide each year are published simultaneously in Mayo Clinic Proceedings and the European Heart Journal.

Contact: Emma Mason
European Society of Cardiology

Public Release: 2-Jul-2015
Developmental Cell
Hippo dances with hormones
In fruit flies, the abnormal growth induced by Hippo pathway disruption depends on genes involved in responding to the steroid hormone ecdysone. This has potential implications for human biology, since the Hippo pathway is involved in suppressing cancer growth and forming embryonic stem cells.
NIH/National Institute of General Medical Sciences, NIH/National Cancer Institute

Contact: Quinn Eastman
Emory Health Sciences

Public Release: 1-Jul-2015
Nature Communications
How removing a protein slows blood vessel growth in tumors
Scientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumors which have spread to the brain, a common location which breast cancer can spread to.

Contact: Ben Jones
University of Leeds

Public Release: 1-Jul-2015
Neuro-Oncology: Clinical Practice
Improved survival in adult patients with low-grade brain tumors
Using clinical data collected over the past decade through a US cancer registry, researchers at the University of California, San Diego School of Medicine demonstrated that significant strides have been made in improving the survival of adult patients with low-grade gliomas, a slow-growing yet deadly form of primary brain cancer.
Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, Doris Duke Foundation, Forbeck Foundation

Contact: Jackie Carr
University of California - San Diego

Public Release: 1-Jul-2015
The EMBO Journal
Live imaging reveals how wound healing influences cancer
Researchers in the United Kingdom and Denmark have studied the 'see-through' larvae of zebrafish to reveal how wound healing leads to melanoma.

Contact: Barry Whyte

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona reveal.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC
Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 1-Jul-2015
New drug for neuroblastoma shows promise in phase I study
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, M.D., and the Neuroblastoma and Medulloblastoma Translational Research Consortium, DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population.

Contact: Rick Jensen
Spectrum Health

Public Release: 1-Jul-2015
Cancer Cell
Experimental drug combined with standard chemo may shrink ovarian cancers
Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.
National Institutes of Health, Conquer Cancer Foundation, HERA Women's Cancer Foundation, Ovarian Cancer Research Fund

Contact: Vanessa Wasta
Johns Hopkins Medicine

Public Release: 1-Jul-2015
Molecular Cancer Therapeutics
Subcutaneous administration of multispecific antibody improves tumor treatment
Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research. According to the scientists, the findings published in the journal Molecular Cancer Therapeutics could lead to shorter hospital stays, among other benefits for patients.
Bayerische Forschungsstiftung

Contact: Dr. Ralph Mocikat
Helmholtz Zentrum München - German Research Center for Environmental Health

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.
Genentech Inc.

Contact: Samiha Khanna
Duke University Medical Center

Public Release: 1-Jul-2015
International Journal of Radiation Oncology, Biology and Physics
Many patients with advanced form of larynx cancer not receiving recommended treatment
Despite findings of previous studies and published guidelines, nearly two-thirds of patients with T4a larynx ('voice box') cancer are not receiving a total laryngectomy (surgical removal of the larynx), the recommended form of treatment, and as a result, have significantly worse survival rates versus those treated with a total laryngectomy, a new study published in the International Journal of Radiation Oncology, Biology and Physics by experts at Penn Medicine found.

Contact: Katie Delach
University of Pennsylvania School of Medicine

Public Release: 30-Jun-2015
ACS Nano
Chitosan-coated, chemotherapy-packed nanoparticles may target cancer stem cells
Nanoparticles packed with a clinically used chemotherapy drug and coated with an oligosaccharide derived from the carapace of crustaceans might effectively target and kill cancer stem-like cells, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
American Cancer Society Research Scholar Grant and Pelotonia

Contact: Darrell E. Ward
Ohio State University Wexner Medical Center

Public Release: 30-Jun-2015
Colon cancer: Taking a step back to move forward
Recent Weizmann Institute studies are revealing a complex picture of cancer progression in which certain genes that drive tumor growth in the earlier stages get suppressed in later stages -- taking a step back to move forward.

Contact: Yael Edelman
Weizmann Institute of Science

Public Release: 30-Jun-2015
Bulletin of the World Health Organization
Epidemic of obesity and overweight linked to increased food energy supply
This study investigates the associations between changes in national food energy supply and average population body weight in 24 high-, 27 middle- and 18 low-income countries. The authors found that the association between change in energy supply and change in weight was statistically significant overall, with findings suggesting that increases in food energy supply are sufficient to explain increases in average population weight.
University of Auckland Vice Chancellor's Strategic Fund, National Institutes of Health

Contact: Fiona Fleck
Bulletin of the World Health Organization

Public Release: 30-Jun-2015
Scientific Reports
Similarities between embryos and breast tumors identified
It may seem incredulous, but breast tumors may have something in common with embryos... at least in mice, say researchers at The University of Texas MD Anderson Cancer Center.

Contact: Ron Gilmore
University of Texas M. D. Anderson Cancer Center

Public Release: 30-Jun-2015
Journal of Clinical Oncology
Citrus fruit consumption may be associated with increased melanoma risk
A new analysis of dietary patterns among more than 100,000 Americans suggests that frequent consumption of citrus -- namely whole grapefruit and orange juice -- may be associated with an increased risk of melanoma. Melanoma risk was 36 percent higher in people who consumed citrus fruit or juice at least 1.6 times daily compared to those who consumed them less than twice per week.

Contact: Alise Fisher
American Society of Clinical Oncology

Public Release: 30-Jun-2015
Scientific Reports
Atomic force microscope advance leads to new breast cancer research
Researchers who developed a high-speed form of atomic force microscopy have shown how to image the physical properties of live breast cancer cells, for the first time revealing details about how deactivation of a key protein may lead to metastasis.
National Science Foundation, National Institutes of Health

Contact: emil Venere
Purdue University

Public Release: 30-Jun-2015
Technology in Cancer Research & Treatment
Does radiation from X-rays and CT scans really cause cancer?
In recent years, there has been widespread media coverage of studies purporting to show that radiation from X-rays, CT scans and other medical imaging causes cancer. But such studies have serious flaws, including their reliance on an unproven statistical model, according to a recent article in the journal Technology in Cancer Research & Treatment.

Contact: Jim Ritter
Loyola University Health System

Public Release: 30-Jun-2015
Protein's impact on colorectal cancer is dappled
Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates.
National Institutes of Health, Burroughs Wellcome Fund, American Cancer Society

Contact: Scott LaFee
University of California - San Diego

Public Release: 29-Jun-2015
Sugary drinks linked to high death tolls worldwide
Consumption of sugary drinks may lead to an estimated 184,000 adult deaths each year worldwide, according to research published today in the journal Circulation and previously presented as an abstract at the American Heart Association Council on Epidemiology and Prevention in 2013.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Heart, Lung and Blood Institute, Bill & Melinda Gates Foundation

Contact: Andrea Grossman
Tufts University, Health Sciences Campus

Public Release: 29-Jun-2015
Proceedings of the National Academy of Sciences
Treatment with PI3K inhibitors may cause cancers to become more aggressive and metastatic
The enzyme PI3K appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target. However, PI3K inhibitors have only shown modest clinical activity. Now, new research from The Wistar Institute shows that treatment with PI3K inhibitors alone may actually make a patient's cancer even worse by promoting more aggressive tumor cell behavior and increasing the cancer's potential of spreading to other organs.
National Institutes of Health, Prostate Cancer Research Program, Joint Grant in Molecular Medicine from Fondazione IRCCS Ca' Granda, Instituto Nazionale Genetica Molecolare

Contact: Ben Leach
The Wistar Institute

Public Release: 29-Jun-2015
Journal of Clinical Oncology
Researchers define unique group of high-risk lymphoma patients
About 20 percent of follicular lymphoma patients consistently experience their disease coming back within two years of being treated with the latest therapies. New research confirms that patients in this group have very poor survival outcomes; 50 percent die in five years. People who relapse early may have a disease with distinctly different biology and should not be approached the same at diagnosis nor at the time of relapse in terms of therapies.
Genentech, F. Hoffmann-La Roche

Contact: Leslie Orr
University of Rochester Medical Center

Public Release: 29-Jun-2015
Molecular Oncology
Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed -- and what to do about it.
National Institutes of Health

Contact: Kevin Punsky
Mayo Clinic

Public Release: 29-Jun-2015
Nature Communications
Danish researchers map important enzyme in the fight against cancer
Researchers from the University of Copenhagen have discovered what regulates an enzyme that is central to the growth of cancer tumors. This could be of great value to future cancer treatment.

Contact: Sarah Dombernowsky
University of Copenhagen The Faculty of Health and Medical Sciences

Showing releases 1026-1050 out of 1299.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

  Search News Releases